Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 50 entries
Sorted by: Best Match Show Resources per page
Dopamine measurement during prolonged deep brain stimulation: a proof-of-principle study of paired pulse voltammetry.

Biomedical engineering letters

Paek SB, Knight EJ, Chang SY, Lujan JL, Jang DP, Bennet KE, Lee KH.
PMID: 24688801
Biomed Eng Lett. 2013 Mar 01;3(1):22-31. doi: 10.1007/s13534-013-0086-y.

PURPOSE: Deep Brain Stimulation (DBS) has been effective in treating various neurological and psychiatric disorders; however, its underlying mechanism hasn't been completely understood. Fast scan cyclic voltammetry (FSCV) is a valuable tool to elucidate underlying neurotransmitter mechanisms of DBS,...

Cite
Paek SB, Knight EJ, Chang SY, et al. Dopamine measurement during prolonged deep brain stimulation: a proof-of-principle study of paired pulse voltammetry. Biomed Eng Lett. 2013;3(1):22-31doi: 10.1007/s13534-013-0086-y.
Paek, S. B., Knight, E. J., Chang, S. Y., Lujan, J. L., Jang, D. P., Bennet, K. E., & Lee, K. H. (2013). Dopamine measurement during prolonged deep brain stimulation: a proof-of-principle study of paired pulse voltammetry. Biomedical engineering letters, 3(1), 22-31. https://doi.org/10.1007/s13534-013-0086-y
Paek, Seungleal Brian, et al. "Dopamine measurement during prolonged deep brain stimulation: a proof-of-principle study of paired pulse voltammetry." Biomedical engineering letters vol. 3,1 (2013): 22-31. doi: https://doi.org/10.1007/s13534-013-0086-y
Paek SB, Knight EJ, Chang SY, Lujan JL, Jang DP, Bennet KE, Lee KH. Dopamine measurement during prolonged deep brain stimulation: a proof-of-principle study of paired pulse voltammetry. Biomed Eng Lett. 2013 Mar 01;3(1):22-31. doi: 10.1007/s13534-013-0086-y. PMID: 24688801; PMCID: PMC3969747.
Copy Download .nbib Format: NLM
The Pathogenesis of Lupus Nephritis.

Journal of clinical & cellular immunology

Sterner RM, Hartono SP, Grande JP.
PMID: 25133068
J Clin Cell Immunol. 2014 Apr;5(2). doi: 10.4172/2155-9899.1000205.

Lupus nephritis is a serious potential feature of systemic lupus erythematous (SLE). Though SLE typically cycles through periods of flares and remission, patients often eventually succumb to end-stage kidney or cardiovascular damage. This review of the pathogenesis of lupus...

Cite
Sterner RM, Hartono SP, Grande JP. The Pathogenesis of Lupus Nephritis. J Clin Cell Immunol. 2014;5(2)doi: 10.4172/2155-9899.1000205.
Sterner, R. M., Hartono, S. P., & Grande, J. P. (2014). The Pathogenesis of Lupus Nephritis. Journal of clinical & cellular immunology, 5(2), . https://doi.org/10.4172/2155-9899.1000205
Sterner, Rosalie M, et al. "The Pathogenesis of Lupus Nephritis." Journal of clinical & cellular immunology vol. 5,2 (2014). doi: https://doi.org/10.4172/2155-9899.1000205
Sterner RM, Hartono SP, Grande JP. The Pathogenesis of Lupus Nephritis. J Clin Cell Immunol. 2014 Apr;5(2). doi: 10.4172/2155-9899.1000205. PMID: 25133068; PMCID: PMC4131745.
Copy Download .nbib Format: NLM
Succinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and Epigenetics.

International journal of endocrinology

Her YF, Maher LJ.
PMID: 26294907
Int J Endocrinol. 2015;2015:296167. doi: 10.1155/2015/296167. Epub 2015 Jul 29.

It is counterintuitive that metabolic defects reducing ATP production can cause, rather than protect from, cancer. Yet this is precisely the case for familial paraganglioma, a form of neuroendocrine malignancy caused by loss of succinate dehydrogenase in the tricarboxylic...

Cite
Her YF, Maher LJ. Succinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and Epigenetics. Int J Endocrinol. 2015;2015:296167doi: 10.1155/2015/296167.
Her, Y. F., & Maher, L. J. (2015). Succinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and Epigenetics. International journal of endocrinology, 2015296167. https://doi.org/10.1155/2015/296167
Her, Yeng F, and Maher, L James. "Succinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and Epigenetics." International journal of endocrinology vol. 2015 (2015): 296167. doi: https://doi.org/10.1155/2015/296167
Her YF, Maher LJ. Succinate Dehydrogenase Loss in Familial Paraganglioma: Biochemistry, Genetics, and Epigenetics. Int J Endocrinol. 2015;2015:296167. doi: 10.1155/2015/296167. Epub 2015 Jul 29. PMID: 26294907; PMCID: PMC4532907.
Copy Download .nbib Format: NLM
Blocking Kallikrein 6 promotes developmental myelination.

Glia

Yoon H, Triplet EM, Simon WL, Choi CI, Kleppe LS, De Vita E, Miller AK, Scarisbrick IA.
PMID: 34626143
Glia. 2022 Mar;70(3):430-450. doi: 10.1002/glia.24100. Epub 2021 Oct 09.

Kallikrein related peptidase 6 (Klk6) is a secreted serine protease highly expressed in oligodendrocytes and implicated in demyelinating conditions. To gain insights into the significance of Klk6 to oligodendrocyte biology, we investigated the impact of global Klk6 gene knockout...

Cite
Yoon H, Triplet EM, Simon WL, et al. Blocking Kallikrein 6 promotes developmental myelination. Glia. 2021;70(3):430-450doi: 10.1002/glia.24100.
Yoon, H., Triplet, E. M., Simon, W. L., Choi, C. I., Kleppe, L. S., De Vita, E., Miller, A. K., & Scarisbrick, I. A. (2022). Blocking Kallikrein 6 promotes developmental myelination. Glia, 70(3), 430-450. https://doi.org/10.1002/glia.24100
Yoon, Hyesook, et al. "Blocking Kallikrein 6 promotes developmental myelination." Glia vol. 70,3 (2022): 430-450. doi: https://doi.org/10.1002/glia.24100
Yoon H, Triplet EM, Simon WL, Choi CI, Kleppe LS, De Vita E, Miller AK, Scarisbrick IA. Blocking Kallikrein 6 promotes developmental myelination. Glia. 2022 Mar;70(3):430-450. doi: 10.1002/glia.24100. Epub 2021 Oct 09. PMID: 34626143; PMCID: PMC8732303.
Copy Download .nbib Format: NLM
Manifold medicine: A schema that expands treatment dimensionality.

Drug discovery today

Ung CY, Weiskittel TM, Correia C, Kaufmann SH, Li H.
PMID: 34600126
Drug Discov Today. 2021 Sep 29; doi: 10.1016/j.drudis.2021.09.016. Epub 2021 Sep 29.

Drug discovery currently focuses on identifying new druggable targets and drug repurposing. Here, we illustrate a third domain of drug discovery: the dimensionality of treatment regimens. We formulate a new schema called 'Manifold Medicine', in which disease states are...

Cite
Ung CY, Weiskittel TM, Correia C, et al. Manifold medicine: A schema that expands treatment dimensionality. Drug Discov Today. 2021;doi: 10.1016/j.drudis.2021.09.016.
Ung, C. Y., Weiskittel, T. M., Correia, C., Kaufmann, S. H., & Li, H. (2021). Manifold medicine: A schema that expands treatment dimensionality. Drug discovery today, . https://doi.org/10.1016/j.drudis.2021.09.016
Ung, Choong Yong, et al. "Manifold medicine: A schema that expands treatment dimensionality." Drug discovery today vol. (2021). doi: https://doi.org/10.1016/j.drudis.2021.09.016
Ung CY, Weiskittel TM, Correia C, Kaufmann SH, Li H. Manifold medicine: A schema that expands treatment dimensionality. Drug Discov Today. 2021 Sep 29; doi: 10.1016/j.drudis.2021.09.016. Epub 2021 Sep 29. PMID: 34600126.
Copy Download .nbib Format: NLM
Platelet-rich plasma for the treatment of lichen sclerosus.

Plastic and aesthetic research

Villalpando BK, Wyles SP, Schaefer LA, Bodiford KJ, Bruce AJ.
PMID: 34950752
Plast Aesthet Res. 2021;8. doi: 10.20517/2347-9264.2021.86. Epub 2021 Dec 05.

AIM: Evaluate the clinical effectiveness of platelet-rich plasma as a treatment for lichen sclerosus.METHODS: A systematic review was performed. The electronic databases PubMed, Ovid MEDLINERESULTS: Platelet-rich plasma treatment was subjectively reported to improve quality of life, but objective measures...

Cite
Villalpando BK, Wyles SP, Schaefer LA, et al. Platelet-rich plasma for the treatment of lichen sclerosus. Plast Aesthet Res. 2021;8doi: 10.20517/2347-9264.2021.86.
Villalpando, B. K., Wyles, S. P., Schaefer, L. A., Bodiford, K. J., & Bruce, A. J. (2021). Platelet-rich plasma for the treatment of lichen sclerosus. Plastic and aesthetic research, 8. https://doi.org/10.20517/2347-9264.2021.86
Villalpando, Beija K, et al. "Platelet-rich plasma for the treatment of lichen sclerosus." Plastic and aesthetic research vol. 8 (2021). doi: https://doi.org/10.20517/2347-9264.2021.86
Villalpando BK, Wyles SP, Schaefer LA, Bodiford KJ, Bruce AJ. Platelet-rich plasma for the treatment of lichen sclerosus. Plast Aesthet Res. 2021;8. doi: 10.20517/2347-9264.2021.86. Epub 2021 Dec 05. PMID: 34950752; PMCID: PMC8694569.
Copy Download .nbib Format: NLM
Critical DNA damaging pathways in tumorigenesis.

Seminars in cancer biology

Kloeber JA, Lou Z.
PMID: 33905873
Semin Cancer Biol. 2021 Apr 24; doi: 10.1016/j.semcancer.2021.04.012. Epub 2021 Apr 24.

The acquisition of DNA damage is an early driving event in tumorigenesis. Premalignant lesions show activated DNA damage responses and inactivation of DNA damage checkpoints promotes malignant transformation. However, DNA damage is also a targetable vulnerability in cancer cells....

Cite
Kloeber JA, Lou Z. Critical DNA damaging pathways in tumorigenesis. Semin Cancer Biol. 2021;doi: 10.1016/j.semcancer.2021.04.012.
Kloeber, J. A., & Lou, Z. (2021). Critical DNA damaging pathways in tumorigenesis. Seminars in cancer biology, . https://doi.org/10.1016/j.semcancer.2021.04.012
Kloeber, Jake A, and Lou, Zhenkun. "Critical DNA damaging pathways in tumorigenesis." Seminars in cancer biology vol. (2021). doi: https://doi.org/10.1016/j.semcancer.2021.04.012
Kloeber JA, Lou Z. Critical DNA damaging pathways in tumorigenesis. Semin Cancer Biol. 2021 Apr 24; doi: 10.1016/j.semcancer.2021.04.012. Epub 2021 Apr 24. PMID: 33905873; PMCID: PMC8542061.
Copy Download .nbib Format: NLM
Manifold medicine: A schema that expands treatment dimensionality.

Drug discovery today

Ung CY, Weiskittel TM, Correia C, Kaufmann SH, Li H.
PMID: 34600126
Drug Discov Today. 2022 Jan;27(1):8-16. doi: 10.1016/j.drudis.2021.09.016. Epub 2021 Sep 29.

Drug discovery currently focuses on identifying new druggable targets and drug repurposing. Here, we illustrate a third domain of drug discovery: the dimensionality of treatment regimens. We formulate a new schema called 'Manifold Medicine', in which disease states are...

Cite
Ung CY, Weiskittel TM, Correia C, et al. Manifold medicine: A schema that expands treatment dimensionality. Drug Discov Today. 2021;27(1):8-16doi: 10.1016/j.drudis.2021.09.016.
Ung, C. Y., Weiskittel, T. M., Correia, C., Kaufmann, S. H., & Li, H. (2022). Manifold medicine: A schema that expands treatment dimensionality. Drug discovery today, 27(1), 8-16. https://doi.org/10.1016/j.drudis.2021.09.016
Ung, Choong Yong, et al. "Manifold medicine: A schema that expands treatment dimensionality." Drug discovery today vol. 27,1 (2022): 8-16. doi: https://doi.org/10.1016/j.drudis.2021.09.016
Ung CY, Weiskittel TM, Correia C, Kaufmann SH, Li H. Manifold medicine: A schema that expands treatment dimensionality. Drug Discov Today. 2022 Jan;27(1):8-16. doi: 10.1016/j.drudis.2021.09.016. Epub 2021 Sep 29. PMID: 34600126.
Copy Download .nbib Format: NLM
Manifold medicine: A schema that expands treatment dimensionality.

Drug discovery today

Ung CY, Weiskittel TM, Correia C, Kaufmann SH, Li H.
PMID: 34600126
Drug Discov Today. 2022 Jan;27(1):8-16. doi: 10.1016/j.drudis.2021.09.016. Epub 2021 Sep 29.

Drug discovery currently focuses on identifying new druggable targets and drug repurposing. Here, we illustrate a third domain of drug discovery: the dimensionality of treatment regimens. We formulate a new schema called 'Manifold Medicine', in which disease states are...

Cite
Ung CY, Weiskittel TM, Correia C, et al. Manifold medicine: A schema that expands treatment dimensionality. Drug Discov Today. 2021;27(1):8-16doi: 10.1016/j.drudis.2021.09.016.
Ung, C. Y., Weiskittel, T. M., Correia, C., Kaufmann, S. H., & Li, H. (2022). Manifold medicine: A schema that expands treatment dimensionality. Drug discovery today, 27(1), 8-16. https://doi.org/10.1016/j.drudis.2021.09.016
Ung, Choong Yong, et al. "Manifold medicine: A schema that expands treatment dimensionality." Drug discovery today vol. 27,1 (2022): 8-16. doi: https://doi.org/10.1016/j.drudis.2021.09.016
Ung CY, Weiskittel TM, Correia C, Kaufmann SH, Li H. Manifold medicine: A schema that expands treatment dimensionality. Drug Discov Today. 2022 Jan;27(1):8-16. doi: 10.1016/j.drudis.2021.09.016. Epub 2021 Sep 29. PMID: 34600126; PMCID: PMC8714694.
Copy Download .nbib Format: NLM
NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy.

Cancer immunology research

Wen T, Barham W, Li Y, Zhang H, Gicobi JK, Hirdler JB, Liu X, Ham H, Peterson Martinez KE, Lucien F, Lavoie RR, Li H, Correia C, Monie DD, An Z, Harrington SM, Wu X, Guo R, Dronca RS, Mansfield AS, Yan Y, Markovic SN, Park SS, Sun J, Qin H, Liu MC, Vasmatzis G, Billadeau DD, Dong H.
PMID: 34911739
Cancer Immunol Res. 2021 Dec 15; doi: 10.1158/2326-6066.CIR-21-0539. Epub 2021 Dec 15.

Cytotoxic CD8

Cite
Wen T, Barham W, Li Y, et al. NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. Cancer Immunol Res. 2021;doi: 10.1158/2326-6066.CIR-21-0539.
Wen, T., Barham, W., Li, Y., Zhang, H., Gicobi, J. K., Hirdler, J. B., Liu, X., Ham, H., Peterson Martinez, K. E., Lucien, F., Lavoie, R. R., Li, H., Correia, C., Monie, D. D., An, Z., Harrington, S. M., Wu, X., Guo, R., Dronca, R. S., Mansfield, A. S., Yan, Y., Markovic, S. N., Park, S. S., Sun, J., Qin, H., Liu, M. C., Vasmatzis, G., Billadeau, D. D., & Dong, H. (2021). NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. Cancer immunology research, . https://doi.org/10.1158/2326-6066.CIR-21-0539
Wen, Ti, et al. "NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy." Cancer immunology research vol. (2021). doi: https://doi.org/10.1158/2326-6066.CIR-21-0539
Wen T, Barham W, Li Y, Zhang H, Gicobi JK, Hirdler JB, Liu X, Ham H, Peterson Martinez KE, Lucien F, Lavoie RR, Li H, Correia C, Monie DD, An Z, Harrington SM, Wu X, Guo R, Dronca RS, Mansfield AS, Yan Y, Markovic SN, Park SS, Sun J, Qin H, Liu MC, Vasmatzis G, Billadeau DD, Dong H. NKG7 Is a T-cell-Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. Cancer Immunol Res. 2021 Dec 15; doi: 10.1158/2326-6066.CIR-21-0539. Epub 2021 Dec 15. PMID: 34911739.
Copy Download .nbib Format: NLM
Emerging workforce readiness in regenerative healthcare.

Regenerative medicine

Wyles SP, Monie DD, Paradise CR, Meyer FB, Hayden RE, Terzic A.
PMID: 33622054
Regen Med. 2021 Mar;16(3):197-206. doi: 10.2217/rme-2020-0137. Epub 2021 Feb 24.

The biology of regenerative medicine has steadily matured, providing the foundation for randomized clinical trials and translation into validated applications. Today, the growing regenerative armamentarium is poised to impact disease management, yet a gap in training next-generation healthcare providers,...

Cite
Wyles SP, Monie DD, Paradise CR, et al. Emerging workforce readiness in regenerative healthcare. Regen Med. 2021;16(3):197-206doi: 10.2217/rme-2020-0137.
Wyles, S. P., Monie, D. D., Paradise, C. R., Meyer, F. B., Hayden, R. E., & Terzic, A. (2021). Emerging workforce readiness in regenerative healthcare. Regenerative medicine, 16(3), 197-206. https://doi.org/10.2217/rme-2020-0137
Wyles, Saranya P, et al. "Emerging workforce readiness in regenerative healthcare." Regenerative medicine vol. 16,3 (2021): 197-206. doi: https://doi.org/10.2217/rme-2020-0137
Wyles SP, Monie DD, Paradise CR, Meyer FB, Hayden RE, Terzic A. Emerging workforce readiness in regenerative healthcare. Regen Med. 2021 Mar;16(3):197-206. doi: 10.2217/rme-2020-0137. Epub 2021 Feb 24. PMID: 33622054; PMCID: PMC8656339.
Copy Download .nbib Format: NLM
Pretreatment imaging of peripheral vascular malformations.

Journal of vascular diagnostics

Johnson JB, Cogswell PM, McKusick MA, Binkovitz LA, Riederer SJ, Young PM.
PMID: 25625123
J Vasc Diagn. 2014;2014(2):121-126. doi: 10.2147/JVD.S66467.

Peripheral vascular malformations (VMs) are complex and diverse vascular lesions which require individualized pretreatment planning. Pretreatment imaging using various modalities, especially magnetic resonance imaging and time-resolved magnetic resonance angiography, is a valuable tool for classifying peripheral VMs to allow...

Cite
Johnson JB, Cogswell PM, McKusick MA, et al. Pretreatment imaging of peripheral vascular malformations. J Vasc Diagn. 2014;2014(2):121-126doi: 10.2147/JVD.S66467.
Johnson, J. B., Cogswell, P. M., McKusick, M. A., Binkovitz, L. A., Riederer, S. J., & Young, P. M. (2014). Pretreatment imaging of peripheral vascular malformations. Journal of vascular diagnostics, 2014(2), 121-126. https://doi.org/10.2147/JVD.S66467
Johnson, Joshua B, et al. "Pretreatment imaging of peripheral vascular malformations." Journal of vascular diagnostics vol. 2014,2 (2014): 121-126. doi: https://doi.org/10.2147/JVD.S66467
Johnson JB, Cogswell PM, McKusick MA, Binkovitz LA, Riederer SJ, Young PM. Pretreatment imaging of peripheral vascular malformations. J Vasc Diagn. 2014;2014(2):121-126. doi: 10.2147/JVD.S66467. PMID: 25625123; PMCID: PMC4304669.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 50 entries